Vera Therapeutics, Inc.
NASDAQ:VERABiotechnology
+$0.09 today
- Market cap
- $1.85B
- Beta
- 0.95
- P/E (TTM)
- -6.8
- EPS (TTM)
- -$5.16
Volume 0.95M
Average 1.18M
VERA Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Vera Therapeutics, Inc.NASDAQ: VERA
Stock-Based Compensation · Q2 FY2026 · quarter ended Jun 2026
Stock-based compensation grows, but more slowly than its trailing trend
Q2 FY2026 stock-based compensation of $15.86M rose 67.5% year over year, behind the +71.5% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 20.1% from the prior quarter. Over 3 fiscal years it compounded at +62.2% a year.
Context
- Stock-based compensation increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +67.5% toward the trailing-twelve-month pace of +71.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 37.93M USD
- Year-over-year change
- +82.3%
- 4-year CAGR
- +88.4%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 37.93M | +82.3% |
| FY2024 | 2024-12-31 | 20.8M | +81.0% |
| FY2023 | 2023-12-31 | 11.49M | +29.3% |
| FY2022 | 2022-12-31 | 8.89M | +195.1% |
| FY2021 | 2021-12-31 | 3.01M | — |
Stock-Based Compensation vs competitors
How VERA compares with its peers on the latest reported figures
- VERA's LTM Jun 2026 stock-based compensation of $49.78M is the 2nd largest of the 10 companies compared; the peer median is $34.27M.
- Its year-over-year change of +71.5% is the 3rd highest of 10, against a peer median of +10.4%.
- Over three fiscal years its annual growth of +62.2% compares with a peer median of +9.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $85.94M | -13.0% | -16.6% | — | |
| LTM Jun 2026 | $49.78M | +71.5% | +62.2% | — | |
| LTM Jun 2026 | $43.55M | +10.4% | +7.3% | 9.4% | |
| LTM Mar 2026 | $41.12M | +24.3% | +9.7% | 17.7% | |
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | $36.4M | -7.4% | +94.0% | 492.0% |
| LTM Jun 2026 | $34.27M | +82.5% | +146.7% | 1800.0% | |
| LTM Mar 2026 | $23.96M | +203.5% | +10.1% | — | |
| LTM Mar 2026 | $12.05M | -2.1% | -6.3% | 144.0% | |
| LTM Mar 2026 | $11.09M | +34.6% | +121.4% | — | |
| LTM Mar 2026 | $3.48M | -33.4% | — | 0.9% | |
| Peer median (excluding VERA) | $34.27M | +10.4% | +9.9% | 80.8% | |
Competitors are the stored peer set for VERA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (32.61M) | (89.06M) | (95.99M) | (152.15M) | (299.62M) |
| Depreciation & Amortization | 176K | (846K) | 21K | 105K | 468K |
| Deferred Income Tax | (1.8M) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 3.01M | 8.89M | 11.49M | 20.8M | 37.93M |
| Change in Working Capital | 3.51M | 6.75M | (5.87M) | 2.66M | 22.99M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 475K | 10.61M | (873K) | (3.45M) | 13.91M |
| Other Working Capital | 3.04M | (3.86M) | (5M) | 6.11M | 9.08M |
| Other Non-Cash Items | 4M | 6.67M | (1.84M) | (6.1M) | (2.88M) |
| Operating Cash Flow | (23.71M) | (67.6M) | (92.18M) | (134.68M) | (241.1M) |
| Capital Expenditures | 0 | (62K) | (63K) | (972K) | (630K) |
| Acquisitions (Net) | 796K | 70.49K | 0 | 0 | 0 |
| Purchases of Investments | 0 | (148.49M) | (224.93M) | (711.99M) | (310.45M) |
| Sales of Investments | 0 | 78M | 185.56M | 278.96M | 506.16M |
| Other Investing Activities | (5M) | (70.49K) | 0 | 8.97M | (800K) |
| Investing Cash Flow | (4.2M) | (70.55M) | (39.43M) | (425.03M) | 194.29M |
| Debt Repayment | 4.92M | 19.82M | 24.74M | 0 | 23.34M |
| Common Stock Issued | 51.18M | 86.13M | 115M | 632.54M | 307.48M |
| Common Stock Repurchased | 0 | 0 | 0 | (13K) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (2.22M) | (4.01M) | (6.2M) | (25.85M) | (21.92M) |
| Financing Cash Flow | 53.88M | 101.93M | 133.54M | 606.67M | 308.9M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 25.97M | (36.22M) | 1.93M | 46.97M | 262.08M |
| Free Cash Flow | (23.71M) | (67.66M) | (92.24M) | (135.65M) | (241.73M) |
Vera Therapeutics, Inc.
NASDAQ:VERA
Intrinsic Alpha fair value
Locked
Current Price
$25.58
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.